...
首页> 外文期刊>Nature Communications >Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension
【24h】

Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension

机译:KLF2诱导的肺动脉高压诱导外泌体MicroRNA的治疗潜力

获取原文
           

摘要

Pulmonary arterial hypertension (PAH) is a severe disorder of lung vasculature that causes right heart failure. Homoeostatic effects of flow-activated transcription factor Krüppel-like factor 2 (KLF2) are compromised in PAH. Here, we show that KLF2-induced exosomal microRNAs, miR-181a-5p and miR-324-5p act together to attenuate pulmonary vascular remodelling and that their actions are mediated by Notch4 and ETS1 and other key regulators of vascular homoeostasis. Expressions of KLF2, miR-181a-5p and miR-324-5p are reduced, while levels of their target genes are elevated in pre-clinical PAH, idiopathic PAH and heritable PAH with missense p.H288Y KLF2 mutation. Therapeutic supplementation of miR-181a-5p and miR-324-5p reduces proliferative and angiogenic responses in patient-derived cells and attenuates disease progression in PAH mice. This study shows that reduced KLF2 signalling is a common feature of human PAH and highlights the potential therapeutic role of KLF2-regulated exosomal miRNAs in PAH and other diseases associated with vascular remodelling.
机译:肺动脉高血压(PAH)是一种严重的肺脉管系统,导致正确的心力衰竭。流动活化转录因子Krüppel样因子2(KLF2)的同种静态效应在PAH中受到损害。在这里,我们表明KLF2诱导的外泌体MicroRNA,miR-181a-5p和miR-324-5p作用在一起以衰减肺血管重塑,并且它们的作用由Notch4和ETS1和血管同性化的其他关键调节剂介导。 KLF2,miR-181a-5p和miR-324-5p的表达减少,而其靶基因的水平在临床前P.H288Y KLF2突变中升高了临床前Pah,特发性Pah和遗传性PAH。 miR-181a-5p和miR-324-5p的治疗补充减少了患者衍生细胞中的增殖和血管生成反应,并在PAH小鼠中衰减疾病进展。该研究表明,降低的KLF2信号传导是人PAH的常见特征,并突出KLF2调节外泌体MIRNA在PAH和与血管重塑相关的其他疾病中的潜在治疗作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号